Trade Takeda Pharmaceutical Company Limited - 4502 CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 23.40 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.011022% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.011201% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | JPY | ||||||||
Margin | 5% | ||||||||
Stock exchange | Japan | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Takeda Pharmaceutical Co Ltd ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 4381.66 |
Open* | 4265.16 |
1-Year Change* | -0.41% |
Day's Range* | 4187.06 - 4265.16 |
52 wk Range | 3,900.00-4,873.00 |
Average Volume (10 days) | 5.00M |
Average Volume (3 months) | 83.99M |
Market Cap | 6,938.79B |
P/E Ratio | 35.96 |
Shares Outstanding | 1.57B |
Revenue | 4,154.41B |
EPS | 121.95 |
Dividend (Yield %) | 4.19612 |
Beta | 1.00 |
Next Earnings Date | Feb 1, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 4204.12 | -89.77 | -2.09% | 4293.89 | 4298.28 | 4197.63 |
Mar 27, 2024 | 4381.66 | 5.99 | 0.14% | 4375.67 | 4401.31 | 4368.19 |
Mar 26, 2024 | 4370.59 | 42.30 | 0.98% | 4328.29 | 4379.17 | 4310.34 |
Mar 25, 2024 | 4354.13 | -39.50 | -0.90% | 4393.63 | 4394.82 | 4346.24 |
Mar 22, 2024 | 4398.52 | 32.82 | 0.75% | 4365.70 | 4406.79 | 4355.32 |
Mar 21, 2024 | 4369.69 | -6.18 | -0.14% | 4375.87 | 4404.30 | 4359.31 |
Mar 19, 2024 | 4354.32 | 16.96 | 0.39% | 4337.36 | 4362.01 | 4327.39 |
Mar 18, 2024 | 4350.74 | 23.35 | 0.54% | 4327.39 | 4364.70 | 4320.41 |
Mar 15, 2024 | 4291.49 | 9.47 | 0.22% | 4282.02 | 4325.00 | 4272.54 |
Mar 14, 2024 | 4277.63 | 8.09 | 0.19% | 4269.54 | 4281.92 | 4240.62 |
Mar 13, 2024 | 4259.38 | 15.26 | 0.36% | 4244.12 | 4287.10 | 4238.62 |
Mar 12, 2024 | 4259.98 | -28.51 | -0.66% | 4288.49 | 4289.49 | 4232.64 |
Mar 11, 2024 | 4297.88 | -35.90 | -0.83% | 4333.78 | 4333.78 | 4259.57 |
Mar 8, 2024 | 4339.87 | -6.06 | -0.14% | 4345.93 | 4359.62 | 4323.30 |
Mar 7, 2024 | 4371.59 | -2.29 | -0.05% | 4373.88 | 4413.88 | 4362.19 |
Mar 6, 2024 | 4363.71 | 26.83 | 0.62% | 4336.88 | 4372.18 | 4332.28 |
Mar 5, 2024 | 4332.89 | 3.10 | 0.07% | 4329.79 | 4344.96 | 4294.38 |
Mar 4, 2024 | 4359.72 | -12.16 | -0.28% | 4371.88 | 4389.94 | 4351.23 |
Mar 1, 2024 | 4379.66 | -2.20 | -0.05% | 4381.86 | 4392.13 | 4361.21 |
Feb 29, 2024 | 4374.68 | -41.38 | -0.94% | 4416.06 | 4424.94 | 4372.18 |
Takeda Pharmaceutical Company Limited Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 28, 2024 | ||
Time (UTC) 12:00 | Country JP
| Event Takeda Pharmaceutical Co Ltd Takeda Pharmaceutical Co LtdForecast -Previous - |
Thursday, June 27, 2024 | ||
Time (UTC) 01:00 | Country JP
| Event Takeda Pharmaceutical Co Ltd Annual Shareholders Meeting Takeda Pharmaceutical Co Ltd Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Total revenue | 4027480 | 3569010 | 3197810 | 3291190 | 2097220 |
Revenue | 4027480 | 3569010 | 3197810 | 3291190 | 2097220 |
Cost of Revenue, Total | 1244070 | 1106850 | 994308 | 1089760 | 651729 |
Gross Profit | 2783410 | 2462160 | 2203500 | 2201420 | 1445500 |
Total Operating Expense | 3494180 | 3123810 | 2596860 | 3193730 | 1874650 |
Selling/General/Admin. Expenses, Total | 997309 | 886361 | 875663 | 964737 | 717599 |
Research & Development | 633325 | 526087 | 455833 | 492381 | 368298 |
Depreciation / Amortization | 542443 | 472915 | 421864 | 455420 | 178617 |
Unusual Expense (Income) | 21593 | 100290 | -265230 | 189043 | -41201 |
Other Operating Expenses, Total | 55443 | 31309 | 114422 | 2384 | -2507 |
Operating Income | 533293 | 445198 | 600952 | 97459 | 222577 |
Interest Income (Expense), Net Non-Operating | -158203 | -142628 | -234717 | -158213 | -94965 |
Other, Net | 1 | ||||
Net Income Before Taxes | 375090 | 302571 | 366235 | -60754 | 127612 |
Net Income After Taxes | 317038 | 230166 | 376171 | 44290 | 135080 |
Minority Interest | -21 | -107 | -166 | -49 | 112 |
Net Income Before Extra. Items | 317017 | 230059 | 376005 | 44241 | 135192 |
Net Income | 317017 | 230059 | 376005 | 44241 | 135192 |
Income Available to Common Excl. Extra. Items | 317017 | 230059 | 376005 | 44241 | 135192 |
Income Available to Common Incl. Extra. Items | 317017 | 230059 | 376005 | 44241 | 135192 |
Diluted Net Income | 317017 | 230059 | 376005 | 44241 | 135192 |
Diluted Weighted Average Shares | 1569.87 | 1577.17 | 1573.54 | 1566.2 | 966.897 |
Diluted EPS Excluding Extraordinary Items | 201.938 | 145.868 | 238.955 | 28.2473 | 139.82 |
Dividends per Share - Common Stock Primary Issue | 180 | 180 | 180 | 180 | 180 |
Diluted Normalized EPS | 213.564 | 194.24 | 129.394 | 106.703 | 112.123 |
Interest Expense (Income) - Net Operating | 2112 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 956156 | 1096550 | 1002310 | 972465 | 873289 |
Revenue | 956156 | 1096550 | 1002310 | 972465 | 873289 |
Cost of Revenue, Total | 309772 | 335973 | 305445 | 292882 | 308380 |
Gross Profit | 646384 | 760578 | 696862 | 679583 | 564909 |
Total Operating Expense | 867594 | 949561 | 897869 | 821950 | 874908 |
Selling/General/Admin. Expenses, Total | 254796 | 262299 | 248734 | 231480 | 223429 |
Research & Development | 160944 | 174629 | 154145 | 143607 | 143628 |
Depreciation / Amortization | 133224 | 135576 | 142366 | 131277 | 149283 |
Unusual Expense (Income) | 11243 | 14898 | 33062 | ||
Other Operating Expenses, Total | -2385 | 26186 | 47179 | 22704 | 17126 |
Operating Income | 88562 | 146990 | 104438 | 150515 | -1619 |
Interest Income (Expense), Net Non-Operating | -40647 | -39837 | -39890 | 4959 | -52429 |
Net Income Before Taxes | 47915 | 107153 | 64549 | 155473 | -54047 |
Net Income After Taxes | 31136 | 119149 | 61732 | 105021 | -11375 |
Minority Interest | -2 | -22 | 10 | -7 | 17 |
Net Income Before Extra. Items | 31134 | 119127 | 61742 | 105014 | -11358 |
Net Income | 31134 | 119127 | 61742 | 105014 | -11358 |
Income Available to Common Excl. Extra. Items | 31134 | 119127 | 61742 | 105014 | -11358 |
Income Available to Common Incl. Extra. Items | 31134 | 119127 | 61742 | 105014 | -11358 |
Diluted Net Income | 31134 | 119127 | 61742 | 105014 | -11358 |
Diluted Weighted Average Shares | 1583.78 | 1570.42 | 1563.73 | 1545.71 | 1553.81 |
Diluted EPS Excluding Extraordinary Items | 19.658 | 75.857 | 39.4837 | 67.9392 | -7.30976 |
Dividends per Share - Common Stock Primary Issue | 90 | 0 | 90 | 0 | 90 |
Diluted Normalized EPS | 24.2709 | 82.0233 | 39.4837 | 67.9392 | 6.52092 |
Total Adjustments to Net Income | 0 | ||||
Other, Net | 1 | -1 | 1 |
- Annual
- Quarterly
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Total Current Assets | 2397960 | 2593640 | 2712890 | 2469430 | 2993040 |
Cash and Short Term Investments | 553704 | 875000 | 1002820 | 653436 | 725819 |
Cash & Equivalents | 229557 | 389058 | 335027 | 188640 | 462890 |
Short Term Investments | 324147 | 485942 | 667793 | 464796 | 262929 |
Total Receivables, Net | 681693 | 724377 | 812714 | 784921 | 749119 |
Accounts Receivable - Trade, Net | 575430 | 617517 | 707487 | 670708 | 657681 |
Total Inventory | 986457 | 853167 | 753881 | 759599 | 919670 |
Other Current Assets, Total | 176102 | 141098 | 143478 | 271476 | 598429 |
Total Assets | 13957800 | 13178000 | 12912300 | 12821100 | 13792800 |
Property/Plant/Equipment, Total - Net | 1691230 | 1582800 | 1453920 | 1386370 | 1331930 |
Property/Plant/Equipment, Total - Gross | 2698980 | 2453010 | 2191740 | 2084120 | 1971520 |
Accumulated Depreciation, Total | -1007750 | -870208 | -737818 | -697754 | -639591 |
Goodwill, Net | 4790720 | 4407750 | 4033920 | 4012530 | 4240250 |
Intangibles, Net | 4269660 | 3818540 | 3909110 | 4171360 | 4751170 |
Long Term Investments | 378857 | 330133 | 348350 | 369455 | 299922 |
Other Long Term Assets, Total | 429328 | 445150 | 454110 | 411948 | 176463 |
Total Current Liabilities | 2481940 | 2145730 | 1773180 | 2175900 | 2553050 |
Accounts Payable | 307453 | 295933 | 232105 | 211627 | 212348 |
Notes Payable/Short Term Debt | 256 | 285 | 69 | 5014 | 500002 |
Current Port. of LT Debt/Capital Leases | 339344 | 203708 | 22084 | 581803 | 484944 |
Other Current Liabilities, Total | 1834890 | 1645800 | 1518920 | 1377450 | 1355760 |
Total Liabilities | 7603630 | 7495000 | 7739260 | 8097610 | 8610790 |
Total Long Term Debt | 4042740 | 4141420 | 4613220 | 4506490 | 4766000 |
Long Term Debt | 4042740 | 4141420 | 4613220 | 4506490 | 4766000 |
Deferred Income Tax | 295178 | 473145 | 576542 | 765079 | 783356 |
Minority Interest | 549 | 504 | 4140 | 4003 | 4006 |
Other Liabilities, Total | 783219 | 734202 | 772180 | 646144 | 504372 |
Total Equity | 6354120 | 5683020 | 5173040 | 4723480 | 5181980 |
Common Stock | 1676340 | 1676260 | 1668140 | 1668120 | 1643580 |
Additional Paid-In Capital | 1728830 | 1708870 | 1688420 | 1680290 | 1650230 |
Retained Earnings (Accumulated Deficit) | 1541150 | 1479720 | 1509910 | 1369970 | 1595430 |
Treasury Stock - Common | -100317 | -116007 | -59552 | -87463 | -57142 |
Unrealized Gain (Loss) | 12470 | 22068 | 41983 | 22891 | 46380 |
Other Equity, Total | 1495650 | 912106 | 324131 | 69673 | 303499 |
Total Liabilities & Shareholders’ Equity | 13957800 | 13178000 | 12912300 | 12821100 | 13792800 |
Total Common Shares Outstanding | 1554.53 | 1550.36 | 1563.36 | 1557.77 | 1554.78 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 2462070 | 2472020 | 2397960 | 2595950 | 2745620 |
Cash and Short Term Investments | 333807 | 368609 | 553704 | 726608 | 830069 |
Cash & Equivalents | 318051 | 316380 | 229557 | 685141 | 798137 |
Short Term Investments | 15756 | 52229 | 324147 | 41467 | 31932 |
Total Receivables, Net | 788066 | 825481 | 681693 | 779872 | 800536 |
Accounts Receivable - Trade, Net | 755327 | 792895 | 575430 | 707318 | 759894 |
Total Inventory | 1155870 | 1083370 | 986457 | 927286 | 953450 |
Other Current Assets, Total | 184327 | 194553 | 176102 | 162180 | 161561 |
Total Assets | 14871900 | 14792700 | 13957800 | 13504700 | 14588800 |
Property/Plant/Equipment, Total - Net | 1894140 | 1795320 | 1691230 | 1656420 | 1760330 |
Goodwill, Net | 5301020 | 5182130 | 4790720 | 4690950 | 4994630 |
Intangibles, Net | 4402420 | 4514080 | 4269660 | 3765760 | 4187060 |
Long Term Investments | 416364 | 393529 | 378857 | 369469 | 425766 |
Other Long Term Assets, Total | 395885 | 435665 | 429328 | 426168 | 475451 |
Total Current Liabilities | 2367620 | 2501740 | 2481940 | 2236810 | 2391720 |
Accounts Payable | 421078 | 440924 | 307453 | 381109 | 388616 |
Notes Payable/Short Term Debt | 0 | 0 | 256 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 274841 | 416860 | 339344 | 372019 | 568228 |
Other Current Liabilities, Total | 1671700 | 1643960 | 1834890 | 1483680 | 1434880 |
Total Liabilities | 7801540 | 7871690 | 7603630 | 7328730 | 7875920 |
Total Long Term Debt | 4404360 | 4330250 | 4042740 | 3914880 | 4168420 |
Long Term Debt | 4404360 | 4330250 | 4042740 | 3914880 | 4168420 |
Deferred Income Tax | 232744 | 274356 | 295178 | 413833 | 493229 |
Minority Interest | 673 | 617 | 549 | 520 | 560 |
Other Liabilities, Total | 796141 | 764719 | 783219 | 762681 | 821992 |
Total Equity | 7070350 | 6921050 | 6354120 | 6175980 | 6712930 |
Common Stock | 1676500 | 1676410 | 1676340 | 1676330 | 1676330 |
Additional Paid-In Capital | 1711110 | 1741940 | 1728830 | 1712040 | 1695540 |
Retained Earnings (Accumulated Deficit) | 1446020 | 1490100 | 1541150 | 1507720 | 1530200 |
Treasury Stock - Common | -51246 | -100255 | -100317 | -100314 | -100313 |
Unrealized Gain (Loss) | 18062 | 26682 | 12470 | 13341 | 16819 |
Other Equity, Total | 2269900 | 2086180 | 1495650 | 1366860 | 1894350 |
Total Liabilities & Shareholders’ Equity | 14871900 | 14792700 | 13957800 | 13504700 | 14588800 |
Total Common Shares Outstanding | 1568.89 | 1554.57 | 1554.53 | 1554.52 | 1554.52 |
Property/Plant/Equipment, Total - Gross | 2698980 | ||||
Accumulated Depreciation, Total | -1007750 |
- Annual
- Quarterly
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Net income/Starting Line | 317038 | 230166 | 376171 | 44290 | 109014 |
Cash From Operating Activities | 977156 | 1123100 | 1010930 | 670381 | 328301 |
Cash From Operating Activities | 664400 | 583151 | 559671 | 583649 | 272446 |
Non-Cash Items | 327626 | 252109 | 12308 | 172928 | 39061 |
Cash Taxes Paid | 185966 | 140423 | 201687 | 226768 | 44909 |
Cash Interest Paid | 108555 | 108207 | 107350 | 127211 | 34914 |
Changes in Working Capital | -331908 | 57679 | 62781 | -130486 | -92220 |
Cash From Investing Activities | -607102 | -198125 | 393530 | 292119 | -2835700 |
Capital Expenditures | -633689 | -186037 | -236468 | -217710 | -134114 |
Other Investing Cash Flow Items, Total | 26587 | -12088 | 629998 | 509829 | -2701580 |
Cash From Financing Activities | -709148 | -1070260 | -1088350 | -1005210 | 2946240 |
Financing Cash Flow Items | -117732 | -108592 | -142352 | -132804 | -71143 |
Total Cash Dividends Paid | -279416 | -283665 | -283357 | -282582 | -142952 |
Issuance (Retirement) of Stock, Net | -26929 | -77531 | -2141 | -3737 | -1172 |
Issuance (Retirement) of Debt, Net | -285071 | -600477 | -660504 | -586090 | 3161500 |
Foreign Exchange Effects | 22929 | 28758 | 12501 | -21766 | -31269 |
Net Change in Cash | -316165 | -116527 | 328608 | -64479 | 407571 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 317038 | 285903 | 166753 | 105021 | 230166 |
Cash From Operating Activities | 977156 | 683463 | 305234 | 84241 | 1123100 |
Cash From Operating Activities | 664400 | 502990 | 326110 | 158283 | 583151 |
Non-Cash Items | 327626 | 218641 | 140497 | 51740 | 252109 |
Cash Taxes Paid | 185966 | 165066 | 109217 | 20855 | 140423 |
Cash Interest Paid | 108555 | 86563 | 52719 | 22770 | 108207 |
Changes in Working Capital | -331908 | -324071 | -328126 | -230803 | 57679 |
Cash From Investing Activities | -607102 | -168610 | -121920 | -94714 | -198125 |
Capital Expenditures | -633689 | -189609 | -138985 | -98376 | -186037 |
Other Investing Cash Flow Items, Total | 26587 | 20999 | 17065 | 3662 | -12088 |
Cash From Financing Activities | -709148 | -702548 | -267593 | -215717 | -1070260 |
Financing Cash Flow Items | -117732 | -92527 | -52761 | -22786 | -108592 |
Total Cash Dividends Paid | -279416 | -268997 | -140007 | -128873 | -283665 |
Issuance (Retirement) of Stock, Net | -26929 | -26929 | -26929 | -26929 | -77531 |
Issuance (Retirement) of Debt, Net | -285071 | -314095 | -47896 | -37129 | -600477 |
Foreign Exchange Effects | 22929 | 23141 | 32720 | 22485 | 28758 |
Net Change in Cash | -316165 | -164554 | -51559 | -203705 | -116527 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Takeda Pharmaceutical Company Limited Company profile
About Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Financial summary
BRIEF: For the nine months ended 31 December 2021, Takeda Pharmaceutical Co Ltd revenues increased 11% to Y2.696T. Net income applicable to common stockholders increased 35% to Y241.42B. Revenues reflect Intellectual Property And Service Revenue segment increase from Y69.04B to Y210.55B, Pharmaceutical Business segment increase of 5% to Y2.485T, Northern America segment increase of 9% to Y1.297T, Japan segment increase of 22% to Y530.25B.
Equity composition
FY'94-02 WAS were estimated. FY'04 Name changed from Takeda Chemical Industries, Ltd. to Takeda Pharmaceutical Company Limited. All 1&3Q, WAS were estimated and used as O/S. FY'08 Q3 WAS=O/S. FY'11 Q3 DWAS is estimated.
Industry: | Pharmaceuticals (NEC) |
4階
日本橋本町二丁目1番1号
CHUO-KU
TOKYO-TO 103-8668
JP
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com